Stockscreener 앱 받기
58.11
2.12%
-1.26
시간 외 거래:
58.23
0.12
+0.21%
전일 마감가:
$59.37
열려 있는:
$59.21
하루 거래량:
12.44M
Relative Volume:
0.93
시가총액:
$118.34B
수익:
$48.19B
순이익/손실:
$7.06B
주가수익비율:
16.80
EPS:
3.4587
순현금흐름:
$12.85B
1주 성능:
-1.42%
1개월 성능:
-3.63%
6개월 성능:
+29.08%
1년 성능:
-3.28%
1일 변동 폭
$58.09
$59.64
1주일 범위
$58.09
$60.80
52주 변동 폭
$42.52
$62.89
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.11 | 120.91B | 48.19B | 7.06B | 12.85B | 3.4587 |
|
LLY
Lilly Eli Co
|
917.50 | 819.81B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.60 | 571.52B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
206.23 | 368.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.93 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
148.19 | 285.86B | 54.72B | 14.02B | 15.32B | 7.1855 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Swiss Life Asset Management Ltd Purchases 68,565 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Wilmington Savings Fund Society FSB Has $5.24 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026 - The Joplin Globe
Bristol-Myers Squibb Co Stock (ISIN: US1101221083) Faces Mixed Signals After Q4 Earnings Miss Amid S - AD HOC NEWS
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation - Cadillac News
BMS brings ‘Emily in Paris’ star and cancer survivor Ashley Park aboard campaign honoring oncologists - Fierce Pharma
Merck vs. Bristol Myers: Which pharma stock is a better pick in 2026? - MSN
WBI Investments LLC Has $2.70 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
US FDA approves J&J's oral psoriasis pill - Reuters
Danske Bank A S Makes New $71.59 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Stake Boosted by Achmea Investment Management B.V. - MarketBeat
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
Physician Views Preview: Can BMS' Sotyktu provide a new oral standard of care for psoriatic arthritis? - FirstWord Pharma
Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study - TipRanks
Jefferies raises Bristol-Myers Squibb stock price target on trial data - Investing.com
Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff? - Labiotech.eu
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Yahoo Finance
HSBC Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60 - 富途牛牛
Bristol Myers Squibb Company $BMY Stock Position Increased by Gotham Asset Management LLC - MarketBeat
Bristol Myers Squibb Company $BMY Stock Position Decreased by Brevan Howard Capital Management LP - MarketBeat
Raymond James reiterates Market Perform on Bristol-Myers Squibb stock By Investing.com - Investing.com Canada
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Raymond James reiterates Market Perform on Bristol-Myers Squibb stock - Investing.com
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Pick Now? - TradingView
Chevy Chase Trust Holdings LLC Sells 35,963 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
BNP Paribas Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Cannell & Spears LLC Has $11.41 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Acquired by Aquatic Capital Management LLC - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Has $29.60 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Ameriprise Financial Inc. Has $1.46 Billion Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
M&T Bank Corp Has $34.43 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Prudential PLC Acquires 36,159 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY is Independent Franchise Partners LLP's 2nd Largest Position - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Dodge & Cox - MarketBeat
Cadence Bank Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb to make immune cell cancer therapies in Japan - Nikkei Asia
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Quadrature Capital Ltd Purchases Shares of 532,436 Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Martingale Asset Management L P - MarketBeat
Mackenzie Financial Corp Buys 149,701 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
143,691 Shares in Bristol Myers Squibb Company $BMY Acquired by Entropy Technologies LP - MarketBeat
Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors - ChartMill
Bristol Myers Squibb Company $BMY Shares Sold by Employees Retirement System of Texas - MarketBeat
Bokf Na Boosts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Arrowstreet Capital Limited Partnership Has $669.01 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Colgate-Palmolive Elects Christopher Boerner, Ph.D. to Board of Directors - citybiz
Colgate-Palmolive raises dividend, adds Bristol Myers CEO to board By Investing.com - Investing.com India
Bristol Myers CEO joins Colgate-Palmolive (NYSE: CL) board - Stock Titan
Is Bristol Myers' Deep Pipeline the Key to Future Growth? - The Globe and Mail
KLCM Advisors Inc. Sells 17,799 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by Franklin Resources Inc. - MarketBeat
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
0.99%
자본화:
|
볼륨(24시간):